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Abstract
 
Human melanoma cells frequently express CC chemokine receptor (CCR)10, a receptor
whose ligand (CCL27) is constitutively produced by keratinocytes. Compared with B16 murine
melanoma, cells rendered more immunogenic via overexpression of luciferase, B16 cells that
overexpressed both luciferase and CCR10 resisted host immune responses and readily formed
tumors. In vitro, exposure of tumor cells to CCL27 led to rapid activation of Akt, resistance to
cell death induced by melanoma antigen-specific cytotoxic T cells, and phosphatidylinositol-3-
kinase (PI3K)–dependent protection from apoptosis induced by Fas cross-linking. In vivo,
cutaneous injection of neutralizing antibodies to endogenous CCL27 blocked growth of
CCR10-expressing melanoma cells. We propose that CCR10 engagement by locally produced
CCL27 allows melanoma cells to escape host immune antitumor killing mechanisms (possibly
through activation of PI3K/Akt), thereby providing a means for tumor progression.
Key words: metastasis • chemokine receptor • cancer • cell signaling
 
Introduction
 
Malignant melanoma is a potentially fatal skin cancer that is
increasing in incidence (1). The ability of tumor cells to
avoid immune surveillance is likely to be central to the
progression of melanoma and other cancers, and many
mechanisms have been described which, in theory, enable
cancers to escape immune-mediated cell death (2).
Because engagement of Fas on tumor cells by Fas ligand
(FasL)-expressing NK cells and CTLs constitutes a major
mechanism by which immune cells kill tumors, tumor cells
have evolved several strategies to escape Fas-mediated cell
death. Malignant cells may down-regulate surface Fas (3) to
avoid engagement by FasL or begin to express FasL them-
selves in order to kill attacking immune cells (4). Some
tumors, including melanoma, up-regulate FLICE-like in-
hibitory protein (FLIP), which blocks the action of caspase-8
in the Fas death pathway (5). Thus, antagonism of tumor-
associated signaling pathways that interfere with Fas-mediated
cell death might enhance the effectiveness of cancer therapy.
In this paper, we explore the role of chemokine recep-
tors in the context of tumor escape from immune cell
clearance mechanisms. Chemokine receptors are comprised
of a family of G protein–coupled, seven-transmembrane–
spanning proteins that bind primarily to four groups of
homologous chemokine ligands (6). Although cancer cells
produce a variety of chemokine ligands that may be in-
volved in neoangiogenesis, the attraction and retention of
inflammatory cells, and proliferation (7), tumor cells express
a limited repertoire of chemokine receptors (7, 8). These
receptors play distinct roles in distant organ metastasis (via
CXC chemokine receptor [CXCR]4) (8, 9) and nodal
metastasis (via CC chemokine receptor [CCR]7) (10, 11).
Interestingly, many melanoma cell lines express the che-
mokine receptor CCR10 in conjunction with CCR7 and
CXCR4 (8). CCR10 (12, 13) is expressed by a population
of skin-homing memory T cells, but it can also be detected
on endothelial cells and cytokine-stimulated melanocytes
(13). CCR10 has two known chemokine ligands: CCL27
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(14) and CCL28 (15). CCL27 is unique among chemo-
kines because it is selectively and constitutively produced in
skin by epidermal keratinocytes (14), and it has been shown
to play a role in T cell homing to inflamed skin (16, 17).
CCL27’s role in melanoma pathogenesis has not been de-
lineated.
Whereas B16 cells are normally poorly immunogenic
and aggressively form tumors in syngeneic mice, we ob-
served that transduction with luciferase rendered tumor
cells less aggressive, which allowed the recipient mice to
generate effective anti–tumor responses after implantation
of these cells into ear skin. Using this model, we assessed
the effects of CCR10 expression on the growth and meta-
static characteristics of CCR10-positive tumor cells. Col-
lectively, our results suggest a novel mechanism that may
enable melanoma cells to evade the host immune response
through the expression of specific chemokine receptors.
 
Materials and Methods
 
Animals, Reagents, and Cell Lines.
 
Female C57BL/6 mice (9)
(8–12 wk old) were used in all experiments. 6-wk-old FasL
 
gld
 
mice on the C57BL/6 background were purchased from Jackson
Laboratories and used at 8 wk of age (i.e., before the develop-
ment of characteristic lymphoproliferative disease [18]). All ani-
mal experiments were conducted with the approval of the NCI
Animal Use and Care Committee. Syngeneic B16/F1 melanoma
cells (19) were grown in DME (GIBCO BRL) with 10% heat-
inactivated FCS and supplements (10). Wortmannin, LY294002,
and PD98059 were purchased from Sigma-Aldrich.
 
Retroviral Transduction of B16/F1 Melanoma Cells.
 
Mouse
CCR10 cDNA (12) (a gift from Dr. Gerald Graham, Beatson In-
stitute, Glasgow, Scotland) was subcloned into the pLNCX2 ret-
roviral vector (CLONTECH Laboratories). B16/F1 melanoma
cells were transduced with cDNA for CCR10 as described previ-
ously with G418-based selection (9, 10). The pLNCX2- and
CCR10-transduced tumor lines were transduced again with fire-
fly (
 
Photinus pyralis
 
) luciferase cDNA and maintained with puro-
mycin. For convenience, the CCR10-luciferase B16 cell line is
hereby referred to as CCR10-B16. The CCR10-B16 cell line
expressed a 42-kD protein band by Western blotting for CCR10
and showed specific calcium flux with the addition of CCL27
(Fig. S1, A and B, available at http://www.jem.org/cgi/content/
full/jem.20030593/DC1). The human CXCR4-luciferase–trans-
duced cell line, CXCR4-B16, and the control vector-luciferase–
transduced line, pLNCX2-B16, were maintained in DME with
10% FCS, G418, and puromycin (9). Luciferase activity per cell
was comparable in all cell lines (pLNCX2-, CXCR4-, and
CCR10-B10). Similar in vivo phenotypes (see Results) were ob-
served using CCR10- and pLNCX2-transduced cells derived
from three or more separate transductions with each retroviral
construct.
 
Immunohistochemistry and Western Blotting.
 
Immunohisto-
chemistry (IHC) and Western blotting for CCR10 were per-
formed using goat anti–human CCR10 (CI0126) and anti–mouse
CCR10 (CI0127) polyclonal antibodies, respectively, from Cap-
ralogics. For detection of phospho-Akt (p-Akt) at serine 473, se-
rum-starved CCR10-B16 cells (5 
 
  
 
10
 
4
 
/well) were preincubated
for 2 h at 37
 
 
 
C with or without various kinase inhibitors
(LY294002, wortmannin, PD98059; Sigma-Aldrich), and pertussis
toxin (Calbiochem) before addition of CCL27. Cells were lysed
 
and analyzed by Western blotting using anti–p-Akt (Ser 473) and
anti-total Akt antibodies (Cell Signaling Technology). A rabbit
anti–p-Akt antibody (9277; Cell Signaling Technology) was used
for IHC of formalin-fixed tumor sections as described (20).
 
Quantitative RT-PCR.
 
Quantitative RT-PCR was per-
formed as described previously (10) using the following primer
pairs: human CCR10, forward, 5
 
 
 
-GGGGATGAAGAGGACG-
CATACT-3
 
  
 
and
 
 
 
reverse, 5
 
 
 
-CCTGGACATCGGCCTTGT-3
 
 
 
;
CCL27 (mouse), forward, 5
 
 
 
-CTGCTGAGGAGGATTGTC-
CAC-3
 
  
 
and reverse, 5
 
 
 
-CACGACAGCCTGGAGGTGA-3
 
 
 
;
CCL28 (mouse), forward, 5
 
 
 
-CAGGGCTCACACTCATG-
GCT-3
 
  
 
and
 
 
 
reverse, 5
 
 
 
-CCATGGGAAGTATGGCTTCTG-3
 
 
 
.
Results were normalized to expression of GAPDH: forward, 5
 
 
 
-
ACCCACTCCTCCACCTTTGA-3
 
 
 
 and reverse, 5
 
 
 
-CATAC-
CAGGAAATGAGCTTGACAA-3
 
 
 
) and then multiplied by 10
 
7
 
.
 
S.c. Inoculation of Transduced Cell Lines.
 
CCR10- and pLNCX2-
B16 cells in exponential growth phase were harvested by
trypsinization and washed twice in PBS before injection. For s.c.
footpad injections, cells (4 
 
 
 
 10
 
5
 
 cells in 
 
 
 
20 
 
 
 
l PBS) were in-
jected into the left hind footpads of C57BL/6 mice. For ear in-
jections, 10
 
5
 
 cells in 
 
 
 
20 
 
 
 
l PBS were injected into the subcuta-
neous space under the central dorsal surface of the left ear
immediately above the cartilage. Tumor growth was monitored
by measurement of the two maximum perpendicular tumor di-
ameters. Experiments were performed two to four times each
with similar results.
 
In vivo Luciferase Imaging.
 
Mice were anesthetized with a
mixture of ketamine and xylazine, injected with 
 
d
 
-luciferin (Bi-
otium) (2 mg/mouse) via the intraperitoneal route and imaged
for 1–3 min in a pitch-black chamber with a cooled CCD camera
(Xenogen). Images were analyzed with the LivingImage software
package system (Xenogen). In vitro luciferase quantification was
performed as described (9).
 
Apoptosis and Cytotoxicity Assays.
 
To increase Fas expression,
CCR10-B16 cells were treated with recombinant murine IFN-
 
 
 
(50 ng/ml; Peprotech) for 12–16 h in DME/0.5% FCS. To con-
firm Fas expression, cells were harvested and washed, and then
stained with PE-conjugated anti–mouse Fas mAb (BD Bio-
sciences) (see Fig. 5 A) for flow cytometric analysis using FloJo
analysis software (Tree Star). For induction of apoptosis, IFN-
 
 
 
–
treated CCR10-B16 cells were exposed to 10 ng/ml recombinant
human FLAG-tagged FasL (Apotech) in combination with 1 
 
 
 
g/
ml anti-FLAG M2 mAb (Sigma-Aldrich) for 16 h plus 1 
 
 
 
g/ml
chemokine (when indicated) at 37
 
 
 
C in the presence of 0.5%
FCS as described (21). VAD-fmk (CLONTECH Laboratories)
was used at 1 
 
 
 
M as an inhibitor of Fas-mediated cell death. IFN-
 
 
 
–treated CCR10-B16 cells that had not been exposed to FasL
were stained with annexin V for baseline assessment of apoptosis.
After exposure of B16 cells to apoptosis-inducing conditions for
16 h, attached (and detached) cells were collected from tissue cul-
ture plates for annexin V staining according to manufacturer’s in-
structions (BD Biosciences). Analysis was performed by flow cy-
tometry with FloJo software. P values were based on two-sided,
nonparametric Student’s 
 
t
 
 tests (unless otherwise specified).
For in vitro CTL assays, T cells (PMEL) from transgenic mice
that expressed T cell receptors specific for a H-2D
 
b
 
–restricted,
mouse gp100 (mgp100)–specific peptide (22) were activated by
incubation in culture medium (CM) (consisting of RPMI 1640
with 10% heat inactivated FCS) with 30 IU/ml recombinant hu-
man IL-2 in the presence of 1 
 
 
 
M human gp100
 
25–33
 
 peptide and
used on day 5–10 after the start of culture (23). CCR10-B16 tar-
get cells were treated overnight with IFN-
 
 
 
 (as above) and la-
beled with calcein-AM (Molecular Probes) at 1 
 
 
 
M final concen-T
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tration, washed, and added to round-bottom microtiter plates
(1.5 
 
 
 
 10
 
4
 
/well) with specific ratios of effector PMEL cells for
2.5 h at 37
 
 
 
C. The supernatants were recovered, and calcein re-
lease was measured using a CytoFluor 2350 plate reader (Milli-
pore). Specific lysis 
 
 
 
 ([experimental 
 
 
 
 spontaneous]/[maximal 
 
 
 
spontaneous]) 
 
 
 
 100. Maximal lysis was achieved with 0.1% Tri-
ton X-100, whereas spontaneous lysis was obtained by incubating
target cells alone. The percentage of cytotoxicity was calculated as
the average of triplicate assays.
 
Online Supplemental Material.
 
Fig. S1 shows functional expres-
sion of transduced CCR10 in B16 cells by Western blot analysis
(Fig. S1 A) and calcium flux assay (Fig. S1 B). Fig. S2 indicates in
vivo luciferase imaging of tumor progression. Fig. S3 shows Fax
expression in pLNCX2-B16 footpad tumor. Fig. S4 shows the fate
of pLNCX2-B16 tumor in FasL-deficient mice by luciferase assay
(Fig. S4 A). Fig. S5 shows phospho-Akt staining of pLNCX2-B16
footpad tumor. Fig. S6 indicates mouse CCL27 and CCL26
mRNA expression in various organs. Figs. S1–S6 are available at
http://www.jem.org/cgi/content/full/jem.20030593/DC1.
 
Results
 
Human Melanomas Express CCR10.
 
Whereas CCR10
mRNA expression has been reported in melanoma cell
lines (8), protein expression of CCR10 in primary human
melanoma has not been investigated. We stained primary
cutaneous melanomas from 13 patients with anti–human
CCR10 antibody and observed seven tumors with nearly
100% expression of CCR10 (see Fig. 1 B for a representa-
tive sample), three tumors with 10–50% CCR10 expres-
sion, and three tumors without apparent CCR10 ex-
pression. We also analyzed three samples of cutaneous
metastatic melanoma tissue by quantitative RT-PCR and
observed 
 
 
 
800-fold increases in CCR10 mRNA com-
pared with skin from healthy volunteers (Fig. 1 C). Thus,
both primary and metastatic human melanomas frequently
express CCR10 in situ.
 
Enhanced Regional LN Metastasis and Local Growth of
CCR10-B16 Cells.
 
To characterize the role of CCR10
in a murine model of melanoma growth and metastasis, we
transduced B16/F1 cells with the full-length cDNA-encod-
 
ing murine CCR10 (12). As noted previously (10), B16
cells show negligible levels of mRNA expression for several
chemokine receptors tested, including CCR10. Whereas
CCR10 was not detectable by RT-PCR (not depicted)
and Western blotting in lysates of B16 cells transduced with
the vector alone (pLNCX2-B16) or with CXCR4 cDNA
(Fig. S1 A, lanes 1 and 2), CCR10-transduced B16 cells
(CCR10-B16) expressed a 42-kD protein that was recog-
nized by a specific anti-CCR10 antibody. CCR10-B16
cells underwent a calcium flux in response to CCL27 but
not to CXCL12 (Fig. S1 B). Footpad tumors of CCR10-
B16–injected mice were moderately increased in size (P 
 
 
 
0.003) compared with the tumors from pLNCX2-B16–
injected mice (Fig. 2 A). Strikingly, the popliteal LN from
CCR10-B16–injected mice showed frequent gross me-
tastases (Fig. 2 B). By contrast, pLNCX2-B16 cells rarely
metastasized to the draining LN (Fig. 2 B), a phenotype of
these cells that we had reported previously (10). Luciferase
quantification revealed a mean luciferase activity of 13988
relative light units in the popliteal LN from CCR10-B16–
injected mice versus 21 relative light units for pLNCX2-
B16–injected mice (P 
 
  
 
0.003, 
 
n 
 
  
 
7, Mann-Whitney
test). Thus, in addition to demonstrating a moderate advan-
tage in growth of the primary tumor compared with con-
trol cells, CCR10-B16 cells display a striking increase in
metastasis to the draining LN after injection into the foot-
pads of mice.
 
CCR10-B16 Cell Tumor Progression in the Ear Skin.
 
In
a separate set of experiments, we injected CCR10-B16 and
pLNCX2-B16 cells into the skin superficial to the ear carti-
lage. In contrast to the growth pattern observed with
pLNCX2-B16 cells in the footpad, tumors did not form in
13 of 15 pLNCX2-B16–injected ears (Fig. 2 C). However,
some pLNCX2-B16–injected mice exhibited small (
 
 
 
1
mm) residual, dark macules at the initial inoculation sites
(Fig. 2 D). Interestingly, parental (untransfected) B16/F1
cells (not depicted) and CCR10-transduced B16 cells (Fig.
2 E) grew progressively in the ear skin (Fig. 2, C compared
with E). 13 of 15 (87%) mice injected in the ear skin with
Figure 1. Human primary and metastatic melanomas
express CCR10 protein and mRNA. (A and B) Primary
cutaneous melanoma was probed with anti–human
CCR10 antibodies (B) or species-matched control (A). Mag-
nification is  400. The red color (amino-9-ethycarbazole)
indicates positive staining. (C) Cutaneous melanoma me-
tastases (n   3) and normal human skin (n   2) were analyzed
for CCR10 mRNA expression. The means of the samples
are shown above individual sample results.T
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CCR10-B16 cells developed tumors that were 
 
 
 
4 mm in
diameter (P 
 
  
 
0.001 compared with pLNCX2-B16–
injected mice, Fisher’s exact test). To determine whether
another chemokine receptor, CXCR4, had similar effects
in tumor formation, we injected CXCR4-B16 cells (9)
into mouse ears and found that only 1 of 10 mice devel-
oped tumors (unpublished data).
After inoculation of CCR10-B16 cells into ear skin,
mice developed pronounced ipsilateral cervical LN en-
largement (Fig. 2 F). 14 of 15 (93%) of CCR10-B16–
injected animals developed gross LN metastases, whereas
gross cervical LN metastasis was observed in only 20% (3
out of 15) of pLNCX2-B16–injected mice (P 
 
  
 
0.001,
Fisher’s exact test; Fig. 2 F compared with G). Although
CXCR4-B16 cells did not display an enhanced ability to
form tumors in ears, we did observe enhanced nodal me-
tastasis in 8 of 10 mice injected with these cells, which was
consistent with a postulated role for CXCR4 in nodal me-
tastasis (8).
In vivo imaging based on the presence of luciferase in
both types of tumor cells was also used to detect the pres-
ence of metastases. Light emanating from the primary tu-
mor and ipsilateral cervical LN from CCR10-B16–injected
mice was readily detected, whereas no light signal could be
detected in the cervical region, abdominal cavity, or cra-
nium of pLNCX2-B16–injected mice 20 d after inocula-
tion (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20030593/DC1). Thus, expression of CCR10
was associated with the capacity of CCR10-B16 cells (in
contrast to pLNCX2-B16 cells) to grow in the ear skin and
metastasize to regional draining LN.
 
CCR10 Protects B16 Cells From Host Immune Re-
sponses.
 
When injected into ear skin, 
 
 
 
90% of pLNCX2-
B16–injected skin sites did not show overt tumors. Micro-
scopically, these injected sites contained predominantly
inflammatory cells and rare tumor cells (Fig. 3, A, C, and D)
in sharp contrast to CCR10-B16 cell–injected sites, which
were composed of highly atypical cells that filled the dermis
(Fig. 3 B). To determine if pLNCX2-B16 cell–injected
mice were protected from rechallenge with tumor cells,
mice that did not develop ear tumors after initial challenge
with pLNCX2-B16 cells were rechallenged 30 d later with
pLNCX2-B16 cells in the footpads. No evidence of
growth of pLNCX2-B16 cells was observed 17 d after in-
oculation in rechallenged mice (Fig. 3 E, middle column).
The same lot of pLNCX2-B16 cells, however, formed tu-
mors in the footpads of nonimmunized, naive mice (left
column). Interestingly, injection of CCR10-B16 cells into
vaccinated mice resulted in tumors similar in size (P 
 
 
 
 0.3)
to those arising from pLNCX2-B16 cells injected into na-
ive mice (Fig. 3 E, right column). Thus, injection of
pLNCX2-B16 cells into the ear of mice leads to an effec-
tive host response that resists tumor formation upon rechal-
lenge with the same cells. The expression of CCR10,
Figure 2. Growth and regional
LN metastasis of CCR10- and
pLNCX2-B16 tumor cells.
CCR10- or pLNCX2-B16 cells
were injected into the footpads of
mice. (A) After 21 d, animals were
killed and tumor sizes in the foot-
pads were compared (P   0.003,
n    5 per group). (B) Draining
popliteal LN from injected foot-
pads. (C–E) Representative ears
from mice injected in the dermis
of the ear with pLNCX2-B16
cells (C) showing a residual tumor
macule indicated by the white
arrow (D) and from mice injected
at analogous sites with CCR10-
B16 cells (E) are shown 20 d after
inoculation. Dissection of the
cervical region ipsilateral to the
tumor injection sites reveals a
large cervical LN metastasis in a
CCR10-B16–injected mouse (F),
but not in a pLNCX2-B16–
injected mouse (G; representative
animals are shown in F and G).
Scale bar in B–E is calibrated
in mm.T
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however, allows B16 cells to escape this host response and
form progressive tumors.
 
CCR10 Mediates Resistance to Fas-mediated Apoptosis.
 
The ability of the CCR10-B16 cells (in contrast to the
pLNCX2-B16 cells) to resist immune clearance (Figs. 2 and
3) and our observation of clear Fas protein expression by
pLNCX2-B16 tumor cells in vivo (Fig. S3, available at
http://www.jem.org/cgi/content/full/jem.20030593/DC1)
prompted us to determine if CCR10 activation could regu-
late the Fas death pathway. Resting CCR10-B16 melanoma
cells in vitro expressed low levels of surface Fas protein (Fig.
4 A). Because interferon (IFN)-
 
 
 
 (either in recombinant
form or as produced by cytotoxic T cells [24–26]) is known
to increase Fas expression by melanoma cells, we treated
CCR10-B16 cells with IFN-
 
 
 
, which resulted in uniform
expression of Fas (
 
 
 
92% expression; Fig. 4 A).
We then exposed IFN-
 
 
 
–treated CCR10-B16 cells to
multimerized FasL in the presence or absence of CCL27 to
determine if CCR10 engagement could protect B16 cells
from FasL-triggered apoptosis, which was measured by an-
nexin V staining. In the absence of CCL27, CCR10-B16
cells readily underwent apoptotic cell death after Fas cross-
linking (Fig. 4 B, far left column). The magnitude of an-
nexin V staining was nearly identical to that achieved by
treatment of melanoma cells with the drug camptothecin
(not depicted). In the presence of CCL27, however,
CCR10-B16 cells were more resistant to Fas-mediated
apoptosis, whereas CCL21 (a chemokine that activates
CCR7) could not reduce cell death (Fig. 4 B). Anti-FLAG
antibody alone did not induce apoptosis, and a general cas-
pase inhibitor (VAD-fmk) effectively blocked Fas-mediated
apoptosis, demonstrating the specificity of the assay (Fig. 4
B). While pLNCX2-B16 cells underwent apoptosis in the
presence of multimerized FasL, these cells were not pro-
tected from apoptosis by exposure to CCL27 (Fig. 4 B).
To determine if CCR10 ligation could protect CCR10-
B16 cells from cytotoxicity induced by melanoma antigen-
specific CTLs, we exposed CCR10-B16 (target) cells to in
vitro–activated CD8
 
 
 
 T cells from a transgenic mouse
(PMEL-1), which expressed the V
 
 
 
2V
 
 
 
13 T cell (TCR)
from the H-2D
 
b
 
 restricted, murine gp100–specific clone
#9 T cell (22). PMEL-1 CD8
 
 
 
 T cells are capable of erad-
icating B16 tumors in vivo after adoptive transfer and re-
stimulation (23). PMEL-1 T cells (PMEL) demonstrated
highly efficient killing of IFN-
 
 
 
–stimulated CCR10-B16
cells, even at low effector:target (E:T) ratios (Fig. 4 C). The
caspase inhibitor, VAD-fmk (Fig. 4 C), and the addition of
anti-FasL antibodies (not depicted) both effectively reduced
CCR10-B16 cell killing by PMEL-1 T cells by 
 
 80%.
The addition of CCL27 also resulted in markedly decreased
killing of target cells that was comparable to target killing in
the presence of VAD-fmk. CCL27, however, did not affect
killing of pLNCX2-B16 cells by PMEL T cells, suggesting
that CCL27 was not reducing apoptosis in the CCR10-
B16 cells via effects on T cells. Moreover, by quantitative
RT-PCR, CCR10 expression was largely absent in PMEL
T cells (not depicted). Thus, engagement of CCR10 on
the surface of melanoma cells conferred resistance to Fas-
mediated cell apoptosis induced by recombinant Fas ligand
and by CTLs specific for a bona fide tumor antigen.
Fas and FasL in the Host Response to pLNCX2-B16 Tumor
Cells. To determine if Fas–FasL interactions were critical
for the destruction of pLNCX2-B16 tumors, we injected
pLNCX2-B16 cells into the ear skin of WT C57BL/6
mice and C57BL/6 mice (Faslgld; gld) that had a homozy-
gous inactivating point mutation in the COOH-terminal
region of FasL (27). Strikingly, pLNCX2-B16 cells formed
progressive tumors in the FasL-deficient (gld) mice but not
WT mice, whereas CCR10-B16 cells formed tumors in
both strains (Fig. 4 D, quantified by luciferase assay in Fig.
S4 A, available at http://www.jem.org/cgi/content/full/
jem.20030593/DC1). Moreover, large cervical LN me-
tastases were observed in gld but not WT mice (Fig. S4 B).
The difference in the ability of pLNCX2-B16 cells to form
Figure 3. Antitumor responses in pLNCX2-B16–injected mice. Ear
skin from pLNCX2-B16 (A, C, and D) and CCR10-B16–injected (B)
mice was removed 18 d after inoculation, formalin fixed, and stained with
hematoxylin and eosin. (A and B) Low power ( 25), (C) medium power
( 200), and (D) high power ( 400) views. (E) Tumor-free mice that
had been injected previously with pLNCX2-B16 cells in the ear were
rechallenged in the hind footpad with either pLNCX2-B16 cells (n   5,
middle column) or CCR10-B16 cells (n   7 mice, right column). P  
0.001, CCR10 versus pLNCX2-B16 injected into immunized mice.
Note no tumor growth was observed in the pLNCX2-B16–rechallenged
mice. As a control, pLNCX2-B16 cells were injected into footpads of
age/sex-matched naive mice (n   5 mice, left column). P   0.3, naive
control versus CCR10-B16–rechallenged group.T
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tumors in WT versus gld mice was specific since parental
B16/F1 cells (Fig. 4 E) and RMA murine lymphoma cells
(28; not depicted) readily formed skin tumors in both WT
and gld mice. Thus, Fas antigen is induced in pLNCX2-
B16 tumor cells in vivo, and FasL appears to be critical for
the host antitumor response that prevents pLNCX2-B16
cells from forming tumors in ear skin.
Involvement of Akt and Phosphatidylinositol-3-kinase in
CCR10-mediated Protection from Apoptosis. After engage-
ment with appropriate ligands, chemokine receptors trigger
a complex cascade of intracellular signaling events (29) that
activate MAP kinase family members and the phosphati-
dylinositol-3-kinase (PI3K)/Akt pathway. Because Akt ac-
tivation can inhibit apoptosis caused by a variety of cellular
stresses including administration of Fas (30), we hypothe-
sized that Akt activation contributed to chemokine recep-
tor-mediated protection from apoptosis.
Within 5 min after administration of CCL27 to
CCR10-B16 cells, we observed a strong increase in Akt
phosphorylation at serine 473, a site known to be necessary
for the cell survival activity of Akt (Fig. 5 A). Phosphoryla-
tion of this critical serine residue was nearly completely in-
hibited by selective PI3K inhibitors (wortmannin and
LY294002), and by PTX, but not by the MEK inhibitor,
PD98059 (Fig. 5 A). To detect activation of CCR10-B16
cells by CCL27 in vivo, we stained tissue sections from ears
of mice injected with CCR10- or pLNCX2-B16 cells with
activation state-specific Akt antibodies. Tumors comprised
of CCR10-B16 cells showed increased levels of active Akt
compared with residual pLNCX2-B16 cells found in the
ear (Fig. 5 B). Finally, to demonstrate the significance of
PI3K/Akt signaling in CCL27-mediated protection of
CCR10-B16 cells, IFN- –treated CCR10-B16 cells were
exposed to multimerized FasL in the absence or presence of
Figure 4. Protection of
CCR10-B16 cells from Fas-
mediated apoptotic cell death via
exposure to CCL27. (A) CCR10-
B16 cells were either treated with
IFN-  or with PBS before
staining with anti-CD95 (Fas)
antibody. Iso: isotype control
antibody. (B) IFN- –treated
pLNCX2-  and CCR10-B16
cells were exposed to recombi-
nant FLAG-tagged FasL and
multimerized  with anti-FLAG
antibodies. Note that both tumor
lines showed equivalent low levels
of Fas-staining before treatment,
which were similarly up-regulated
after IFN-  treatment. Cells were
then collected and stained with
propidium iodide (PI) and annexin
V–FITC. Data from PI-negative
B16 cells were quantified using
FloJo software and are presented
as percentage of annexin V–pos-
itive cells. pLNCX2-B16 cells
were not used under the three
right-most conditions. *P   
0.0016 versus FasL (n    3 per
condition). (C) IFN- –treated
CCR10-B16 cells, as in B, were
incubated with antigen-stimulated
PMEL T cells at the indicated
E:T ratios and assessed for cyto-
toxicity. (D) pLNCX2-, CCR10-
B16 (100   103 per ear), (E)
parental  B16/F1 cells (100  
103 cells/ear) were injected into
the ear skin of gld mice or age-
and gender-matched WT C57BL/6
mice (14-d tumor assay) as in-
dicated.T
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CCL27 and/or a PI3K inhibitor. As before, administration
of multimerized FasL alone increased apoptosis (Fig. 5 C,
top row, middle dot plot). When CCL27 was added in
conjunction with multimerized FasL, the increase in an-
nexin V staining was completely blocked (Fig. 5 C, top
row, right dot plot). Pretreating CCR10-B16 cells with
LY294002, however, abrogated protection conferred by
CCL27 (Fig. 5 C, middle row, right dot plot). However,
LY294002 alone did not induce significant cell death (Fig.
5 C, middle row, left dot plot). Treatment with PTX also
rendered CCR10-B16 cells susceptible to Fas-mediated
apoptosis even in the presence of CCL27 (Fig. 5 C, bot-
tom row, right histogram). Therefore, CCL27 protects
CCR10-B16 cells from FasL-induced apoptosis in a PI3K-
and Gi protein–dependent manner.
Anti-CCL27 Neutralizing mAb Prevent Formation of
CCR10-B16 Tumors in Ear Skin. CCL27 is constitutively
produced at the protein level by epidermal keratinocytes
(14, 16). Thus, we postulated that skin-derived CCL27
protected CCR10-B16 cells in the skin from host immune
responses. To test this hypothesis, we injected CCR10-
B16 cells into ear skin either with anti-CCL27 neutralizing
mAb (16) or with isotype-matched control antibodies. This
anti-CCL27 mAb has been shown by others to inhibit the
influx of T cells into skin in vivo (16) and completely in-
hibited downstream p-Akt activation in CCR10-B16 cells
in vitro at a concentration of 100  g/ml (unpublished
data). The anti-CCL27 mAb treatment effectively pre-
vented CCR10-B16 tumor formation (Fig. 6). However,
parental B16/F1 cells that were treated with the same re-
agents under similar conditions showed no differences in
tumor progression, demonstrating that the effect of the
anti-CCL27 mAb on CCR10-B16 cells was specific (Fig.
6). In two independent experiments, a total of zero out of
six animals injected with anti-CCL27 mAb developed gross
CCR10-B16 tumors, whereas six out of six animals in-
jected with the control antibody developed tumors (P  
0.0022, Fisher’s exact test).
Figure 5. Involvement of PI3K and Akt in CCR10-mediated protection from apoptosis. (A) CCR10-B16 cells were exposed to PBS or CCL27
(1  g/ml) for the indicated time in the presence of cell signaling inhibitors (wortmannin (200 nM, WM), LY294002 (10  M, LY), pertussis toxin (200
ng/ml, PTX), and PD98059 (20  M, PD), lysed, and analyzed by Western blot for p-Akt and total Akt. (B) 14 d after inoculation into the dermis,
CCR10-B16 and residual pLNCX2 tumors in the ears were probed for p-Akt expression by IHC. (C) CCR10-B16 cells that had been pretreated for 18 h
with the PI3K inhibitor, LY294002 (10  M), PTX (200 ng/ml), or DMSO alone were exposed to multimerized FasL in the presence and absence of
CCL27 (1  g/ml) for 16 h at 37 C. As a negative control, cells were exposed to the anti-FLAG epitope antibody without prior exposure to FasL
( -FLAG). One of three experiments with similar results.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
CCR10 and Melanoma Immune Evasion 1344
Discussion
Herein, we report that CCR10 is frequently expressed
in primary cutaneous human melanomas but not in mu-
rine (B16) melanoma. To explore the possible function of
CCR10, we transduced B16 melanoma cells with CCR10
cDNA and found three remarkable features of the result-
ing cells: (1) they formed tumors at skin sites where lu-
ciferase-expressing B16 cells could not, (2) they resisted
Fas-mediated apoptosis in vitro in a PI3K-dependent fash-
ion, and (3) they metastasized with high frequency to
draining regional LN.
Unlike control B16 cells, CCR10-B16 cells formed tu-
mors after ear skin injection. Because of the intense inflam-
matory reaction surrounding residual pLNCX2-B16 cells
in the skin, we suspected that a host immune response was
responsible for the destruction of these cells. After observ-
ing Fas expression in pLNCX2-B16 cells injected into the
footpads, we explored the effect of CCR10 on Fas-medi-
ated cell death because the Fas pathway can be critical to
the efficacy of antitumor responses by CTLs and natural
killer cells and to the efficacy of some antitumor drugs (31).
Our results clearly suggested that (1) Fas–FasL is required
for the eradication of pLNCX2-B16 cells in the ear (Fig. 4
D and Fig. S4) and (2) CCR10-mediated signaling protects
B16 tumor cells from Fas-triggered apoptosis in vitro.
Nontransduced parental B16/F1 melanoma cells that
lacked CCR10 expression also formed progressive tumors
in ear skin, which was not surprising since unmanipulated
B16 cells are poorly immunogenic (32). Because these
cells lacked expression of luciferase, it is possible that part
of the host response to the pLNCX2-B16 cells was di-
rected at this neo-antigen. However, the immune re-
sponse that develops after ear injection of pLNCX2-B16
cells is not solely directed at luciferase. We have observed
that pLNCX2-B16–immunized mice (Fig. 3) are also par-
tially protected from tumor formation resulting from foot-
pad injection of parental B16/F1 tumor cells (unpublished
data), suggesting that ear immunization also leads to re-
sponses directed at endogenous melanoma antigens. Fur-
thermore, CCR10-B16 cells were resistant to Fas-depen-
dent cell death (Fig. 4) mediated by CTL that are specific
for a bona fide melanoma tumor antigen, gp100 (22, 33,
34). Thus, CCR10 activation protects tumor cells from
immune responses directed at endogenous as well as non-
endogenous targets.
To explain the potent immune response against
pLNCX2-B16 cells injected in the ear (as opposed to the
footpad), we believe that anatomical factors in the ear per-
mitted rapid movement of tumor cells from the skin to
draining cervical LN that resulted in a potent immunologi-
cal response against pLNCX2-B16 cells (Fig. 3). Indeed, by
in vivo luciferase imaging we have observed the presence
of both pLNCX2- and CCR10-B16 cells in the draining
cervical LN within 5 min of injection into ear skin,
whereas neither cell line accumulated in the popliteal LN
shortly after footpad injections (unpublished data). This dif-
ferential site-specific accumulation of tumor cells in re-
gional LN may be the reason we previously observed
no difference in the ability of CXCR4-B16 cells and
pLNCX2-B16 cells to metastasize to the popliteal LN after
footpad injection (9), whereas in the current work, cervical
LN involvement was observed after injection of CXCR4-
B16 cells into ear skin. Interestingly, others have shown
that early migration of cancer cells to secondary lymphoid
organs may be a factor in enhanced host anti-tumor re-
sponses (35), and direct injection of DCs loaded with mela-
noma tumor antigen into the LN can lead to clinically ef-
fective antimelanoma responses (36).
Although chemokine receptor ligation leads to activation
of multiple intracellular signaling pathways involving Jak-
Stat proteins, MAP kinases, focal adhesion kinases, and
PI3K (29), we focused on the PI3K/Akt pathway because
Akt regulates cellular survival, motility, and protects against
Fas-mediated apoptosis (37). Akt was activated in CCR10-
B16 cells after in vitro exposure to CCL27 and was also
easily detectable in CCR10-B16 tumors in vivo (Fig. 5, A
and B). Of note, exposure of CCR10-B16 cells to
LY294002 reestablished the susceptibility of these cells to
Fas-mediated cell death (Fig. 5 C) in the presence of
CCL27, suggesting that the PI3K/Akt signaling pathway is
critical for chemokine receptor–mediated protection from
apoptosis in vitro. Although these data raise the possibility
that chemokine-mediated up-regulation of PI3K/Akt may
Figure 6. Prevention of CCR10-B16 cell tumor
formation with anti-CCL27 treatment. CCR10-B16
or B16/F1 cells were injected into the ear skin of
mice in an 18-d tumor formation assay. At the time
of injection, the cells were suspended in injection
buffer containing either 100  g/ml of neutralizing
rat anti–mouse CCL27 IgG (16) (clone 68623;
R&D Systems) or 100  g/ml of rat IgG, which
was coinjected with tumor cells in a volume of
20   l. One of two independent experiments
with similar results.T
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be an important factor for tumor progression in vivo, addi-
tional studies will be necessary to validate this proposal.
Substantial staining for active Akt was also observed in
footpad tumors arising from pLNCX2-B16 cells (Fig.
S5, available at http://www.jem.org/cgi/content/full/
jem.20030593/DC1), suggesting CCR10-independent ac-
tivation of Akt. Although precise quantification of pAkt by
IHC has limitations, this may reflect the action of other
regulators of cancer growth, including the epidermal
growth factor receptor, that are upstream activators of
PI3K/Akt (38).
Our observation that CCR10 strongly enhanced LN
metastasis was intriguing but unexpected. Although the
mechanism underlying this result is unclear, it may be re-
lated to enhanced survival of a small number of CCR10-
B16 cells that arrive in the LN after cutaneous injection.
Because neither lymphatics nor LN are likely to express
high levels of CCR10 ligand (8), direct attraction of the
melanoma cells to the lymphatics via CCR10 is an unlikely
possibility. The only other known ligand for CCR10,
CCL28, was also found at low levels in the LN and in the
skin (Fig. S6, available at http://www.jem.org/cgi/
content/full/jem.20030593/DC1). However, CCL27 from
the skin may actually enter the lymphatics for transport to
the LN as has been shown for other chemokines that were
injected into skin (39). Alternatively, CCL27 has been re-
ported to enhance cell migration via unique nuclear signal-
ing (40), and this property may contribute to enhanced
metastatic potential.
The ability of chemokine receptor–mediated signaling to
inhibit apoptosis may not be unique to CCR10. For exam-
ple, activation of CCR9 partially protects lymphoid cells
from both Fas- and cycloheximide-induced apoptosis in
vitro (41), and engagement of CX3CR1 has antiapoptotic
effects in brain microglia (42). Whereas prior studies have
implicated chemokine receptors in the survival of other
types of cells (41, 43, 44), the present study is the first in
vivo demonstration of chemokine receptor–mediated im-
mune evasion by tumor cells.
Although CCL27 is constitutively synthesized in the epi-
dermis (14), CCL27 protein (presumably coming from epi-
dermal cells) is also present in the dermis (16). Thus,
CCL27 may have effects on tumor cells implanted into
dermis because of its ability to cross the basement mem-
brane after synthesis by keratinocytes. The presence of
CCL27 in the skin may potentially explain why CCR10
expression could be advantageous to melanoma, which
arises in the environs of skin and frequently metastasizes to
skin. Interestingly, CXCR4-B16 cells did not form tumors
in ear skin, perhaps because levels of CXCL12 (versus
CCL27) are relatively low in the skin compared with lung
and LN (8).
Our results demonstrate that chemokine receptors may
play critical roles in tumor progression apart from their
ability to affect organ-selective metastasis. Ligation of tu-
mor-associated chemokine receptors by locally produced
chemokines may be a mechanism that promotes cancer cell
survival. Based on our results showing protection of
CCR10-B16 from Fas-triggered apoptosis, we predicted
that inhibition of the CCL27-CCR10 pathway should
make CCR10-B16 cells more susceptible to the host anti-
tumor response. Indeed, CCR10-B16 tumor formation
was markedly reduced by treatment with neutralizing anti-
bodies to CCL27 (Fig. 6). These findings demonstrate that
therapy directed at specific chemokine receptor pathways
may enhance antitumor immunity and may be useful in a
clinical setting.
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